ALT — Analytica Share Price
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | -684.33% |
Financial Summary
Year End 30th Jun | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | AU$m | 1.01 | 0.83 | 0.81 | 0.8 | 0.29 | n/a | n/a | -25.55% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Analytica Limited is an Australia-based product development and commercialization company that is focused on Class I and II medical device products. Its lead product is the PeriCoach System- an e-health treatment system for women who suffer stress urinary incontinence. PeriCoach includes a device, Web portal and smartphone app and the device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via Web portal. The Company is also the developer of the Enhanced Infusion System (EIS), a combination of technologies developed under the project names AutoStart and AutoFlush. It is also commercializing the AutoStart Burette infusion system. The EIS is a simple and inexpensive IV add-in technology to reduce nursing monitoring costs, reduce embolism risk, improve infection control and automatically restart flow after medication delivery during intravenous fluid infusion.
Directors
- Last Annual
- June 30th, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- August 27th, 1985
- Public Since
- October 25th, 2000
- No. of Employees
- 2
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS
- Shares in Issue
- 4,613,801,129

- Address
- PO Box 438, MARYBOROUGH, 4650
- Web
- https://www.analyticamedical.com/
- Phone
- +61 732781950
- Auditors
- Bentleys Brisbane (Audit) Pty Ltd
Upcoming Events for ALT
Similar to ALT
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Orthopaedics
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
FAQ
As of Today at 01:02 UTC, shares in Analytica are trading at AU$0.00. This share price information is delayed by 15 minutes.
Shares in Analytica last closed at AU$0.00 and the price had moved by -50% over the past 365 days. In terms of relative price strength the Analytica share price has underperformed the ASX All Ordinaries Index by -53.5% over the past year.
There is no consensus recommendation for this security.
Find out moreAnalytica does not currently pay a dividend.
Analytica does not currently pay a dividend.
Analytica does not currently pay a dividend.
To buy shares in Analytica you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.00, shares in Analytica had a market capitalisation of .
Here are the trading details for Analytica:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ALT
Based on an overall assessment of its quality, value and momentum Analytica is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Analytica. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +2.05%.
As of the last closing price of AU$0.00, shares in Analytica were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Analytica PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Analytica's management team is headed by:
- Michael Monsour - CHM
- Geoff Daly - CEO
- Bryan Dulhunty - CFO
- Peter Corr - DRC
- Ross Mangelsdorf - NID